Pharmaceutical Technology on MSN1d
Unsafe and unregulated cell therapies being sold in EuropeThe EMA warns of products being sold as dendritic cell therapies with little evidence, but high health risks, in the European ...
Piper Sandler analyst Allison Bratzel reiterated a Buy rating on IO Biotech (IOBT – Research Report) today and set a price target of $10.00.
Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...
Burning Rock Biotech Limited’s BNR share price has dipped by 13.43%, which has investors questioning if this is right time to buy.
When some former MyoKardia execs reunited with $300 million for a new “heart health” biotech earlier this year, they were Get free access to a limited number of articles, plus choose ...
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s share price dropped 5.8% on Tuesday after Truist Financial lowered their price target on the stock from $25.00 to $15.00. Truist ...
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end ...
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price objective trimmed by Truist Financial from $25.00 to $15.00 ...
Biotechnology Instruments Market Growth BURLINGAME, CA, UNITED STATES, February 28, 2025 /EINPresswire.com/ -- The Latest study titled Biotechnology Instruments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback